Ozampic, Wagovi may reverses serious liver disease, suggest studying

According to a new survey, drugs made for diabetes and weight loss can stop or even reverses a serious liver disease.

International studies led by a researcher at the University of Virginia Commonwealth have shown that drug semaglotids, commonly known by brand name Ozampic and Wagovi, are capable of fighting metabolism-related stitohapatitis, or MASH, liver disease and some of its risks.

MASH is characterized by inflammation and stains due to fat in the liver. According to the Cleveland clinic, it affects about 20 percent of adults in the United States and is closely involved with risk factors such as type 2 diabetes and hypertension.

Researchers conducted weekly injections to 800 patients across 37 countries between 2021 and 2023 – either placebo or semaglutide.

More than half of the participants had type 2 diabetes and 75 percent were obese.

After about 17 months of injection, 62.9 percent of semaglutide patients are low in inflammation and fat in their livelihoods; Placebo saw 34 percent of patients with the same results.

It has also reduced liver spots in 37 percent of patients than 23 percent of the placebo.

Semagloted subjects of study have shown to reduce 10.5 percent weight, as well as improving liver enzymes and liver fibrosis measurements.

The top author of the top. Arun Sanal said the survey could offer “new methods committed for millions of patients”.

“If approved, it can provide additional treatment options for patients with mash and fibrosis,” said Saniel. “This is very important, because of a strong connection between the mash and the cardiovascular, metabolic and renal conditions, where semaglutide has shown already established health benefits.”

Sunial team plans to continue research by studying 1,200 participants in 37 countries for five years to view long -term liver issues.